Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency
Go back to Ultragenyx Announces Positive Topline Cohort 3 Results and Improved Longer-Term Cohort 2 Results from Phase 1/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency| ULTRAGENYX PHARM (NASDAQ: RARE) | Delayed: 14.90 +0.02 (0.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.88 | 52 Week High | $117.12 | |||
| Open | $14.77 | 52 Week Low | $46.52 | |||
| Day High | $15.19 | P/E | N/A | |||
| Day Low | $14.75 | EPS | $-1.97 | |||
| Volume | 512,915 | |||||
